COVID-19 new treatment method ‘hyperthermia treatment device’… Research begins in earnest with launch of IVRA > PR Information Data

COVID-19 new treatment method ‘hyperthermia treatment device’… Research begins in earnest with launch of IVRA

Conference held to commemorate the launch of IVRA... Opening a venue for exchange with medical professionals and scholars from around the world

Hyperthermia immunotherapy proves to be effective in treating coronavirus... Announcement of protocol and clinical preparation in full swing

[Medipana News = Reporter Park Seon-hye] With 'Hyperthermia treatment devices' newly proposed as one of the treatments for COVID-19, 'IVRA', an international research cooperation group to prove and utilize them, is attracting attention as it appears that it will drive full-scale activities.

On the 29th, an international conference was held in COEX Conference Room 300 to announce the establishment of the first joint cooperation group IVRA (International Virus Research Alliance) for the treatment of COVID-19.

따라서 IVRA는 이번 국제컨퍼런스를 통해 출범을 알리면서 동시에 20여개국 의료진을 대상으로 온열면역치료에 대한 관심을 높이고 국제적 연구를 실시하기 위한 교류의 장을 만들겠다는 포부다.

Therefore, IVRA aims to announce its launch through this international conference and at the same time create a venue for exchange to increase interest in hyperthermia immunotherapy among medical staff from over 20 countries and conduct international research.

He added, "Unlike past high-frequency devices, this product is easy to operate and has almost no side effects, so it can be used with simple medical expertise. And “There will be almost no deviation by the users.”"

IVRA vice-chairman Kim Sun-man said, “In this clinical trial, we used the principle that when the human body temperature rises, NK cells, which are immune cells, increase the activity explosively, triggering an immune response and attacking virus-infected cells or tumor cells,” he explained “Because the increased NK cells’ activity is maintained for two weeks, the effect appears even with a small number of the hyperthermia treatments.”

REMISSION is a hyperthermia device that raises core heat to nearly 42 degrees in 30 minutes through electrode movement of ions in the cells of the human body. It has been used as a pain relief and cancer treatment device for more than 10 years and has currently been supplied to more than 100 hospitals, including Seoul St. Mary's Hospital. .

The hyperthermia treatment device currently used at Seosan Medical Center is AdipoLABs' REMISSION, a high-frequency medical device that has received certification from the Korean Ministry of Food and Drug Safety, the U.S. FDA registration, and European CE. According to the report, the CT value is around 35 to 40, but internationally, anything over 29.5 is considered negative,” he said. “We believe that these results will enable quick treatment and discharge of patients with mild symptoms, and even prevention will be possible if we use the principle.”

Dr. Yoo said, “The paper and the cases of 20 people are still not enough to prove anything, but I want to use this as a starting point so that we can take the lead in the world.” He emphasized, “If we can create a global protocol and start international clinical trials through this exchange, it will be an opportunity to promote domestic treatments rather than relying only on vaccine imports in the future.”

In addition, “AdipoLABs has decided to donate the device to 20 countries. IVRA plans to create a COVID-19 treatment protocol using the data received through this.”, “We plan to start as quickly as possible by discussing with each country the specific target to select, the number of treatments, and the duration,” he said.

Meanwhile, advisory members at this conference include former Dankook University Medical Center Director Park Woo-sung (Cancer Center Promotion Committee Chair), Catholic University School of Medicine Professor Jang Hong-seok, Yonsei University University Professor Hwang Seong-oh, Catholic University School of Medicine Professor Kang Young-nam, Chung-Ang University School of Medicine Professor Jeong Yun-jae, Soonchunhyang University School of Medicine Professor Kim Ho-jung, and Kyung Hee University University Professor Lee Hyeong-min, Bundang Jesaeng Hospital Center Director Kim Young-sik, Director Jeong Young-ho of Internal Medicine, Yonsei Line Clinic Director An Seong-hwan, Pangyo Yonsei Clinic Shin Hyeong-jin, Korean Balance Medical Association President Kim Kyung-jin, former Integrative Cancer Society President Choi Nak-won, GBA Korea President Oh Sinan Ozturk, Asian Economic Development Committee Chairman Yoon Seok-heon, former Food and Drug Administration Commissioner Kim Jin-soo, IND CEO Jang Chang-don, Eunseong Medical Foundation CEO Jeong Ho-jae A total of 50 medical experts and prominent figures were appointed.

In addition, overseas VIPs include UNWHD Chairman Mohamed Jinna, UMMC Hospital Prof. Ho Gwo Fuang (Malaysia), Dr. Amjath Khan (Mumbai Healthcare Association President), Dr. Ilayaraja (Pondicherry Healthcare Centre), and Dr. Durai (Pondicherry Health Ministry), Ambassadors and commercial officials from over 30 countries around the world also participated.

출처Source : http://m.medipana.com/index_sub.asp?NewsNum=285633